PH94B

Identification

Name
PH94B
Accession Number
DB04968
Description

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.

Type
Small Molecule
Groups
Investigational
Synonyms
Not Available

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Intended for the acute treatment of social phobia.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptor’s location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.

Mechanism of action

There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.

Absorption

Absorbed following nasal administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Monti-Bloch L, Jennings-White C, Dolberg DS, Berliner DL: The human vomeronasal system. Psychoneuroendocrinology. 1994;19(5-7):673-86. [PubMed:7938363]
PubChem Substance
347909864
Wikipedia
PH94B

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentSocial Anxiety Disorder (SAD)1
3Not Yet RecruitingTreatmentSocial Anxiety Disorder (SAD)1
2CompletedTreatmentSocial Anxiety Disorder (SAD) / Social Phobia1
2Not Yet RecruitingTreatmentAdjustment Disorder With Anxious Mood1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on October 21, 2007 22:23 / Updated on June 12, 2020 16:52